IGC Pharma, Inc. NYSE American: IGC

NYSE American: IGC, is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness.

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

The Icahn School of Medicine at Mount Sinai (@IcahnMountSinai) has been added as a clinical site in IGC Pharma’s Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer’s disease. 

Read more: https://t.co/Iq7lcahG5D 

#AlzheimersResearch

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

Agitation remains one of the most prevalent and challenging symptoms in Alzheimer’s disease

Understanding its behavioral patterns is essential for advancing research and supporting the development of more targeted therapeutic strategies

#AlzheimersResearch #IGCPharma

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

On #ClinicalTrialsDay, we recognize the role of structured, patient-centered research in advancing medicine

Scientific rigor, regulatory responsibility, and participant trust remain at the core of progress in Alzheimer’s research

#AlzheimersResearch

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

New Tau-PET biomarker research by IGC Pharma was presented at the 2026 Global Tau Conference

The poster evaluated whether Shannon entropy may quantify tau pathology heterogeneity

Read more: https://t.co/idKCy4z446

#AlzheimersDisease #AIinHealthcare #IGCPharma

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

Understanding demographic differences is essential for advancing research, improving clinical trial design, and refining therapeutic development

(Source: Alzheimer’s Association; National Institute on Aging)

#AlzheimersDisease #IGCPharma

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

Research suggests important differences in how Alzheimer’s disease affects men and women, from prevalence to progression

Here’s what current evidence shows ⬇️

#AlzheimersResearch #Neuroscience

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

Caregiver dynamics add another dimension

Women are more likely to both develop Alzheimer’s and serve as caregivers, shaping how the disease is experienced socially and clinically ⬇️

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

Music is being studied as a neurologically grounded phenomenon in Alzheimer’s disease

Research explores preserved musical memory networks and how music-based interventions may influence mood and behavior

Read more: https://t.co/oHgDSQPalT

#AlzheimersResearch #Neuroscience

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

Times Square marks another step in our journey

A reminder of the global scale of Alzheimer’s disease and the responsibility that comes with advancing research in this field

Scientific rigor and disciplined execution remain at the core of our work

#AlzheimersResearch #Biotech #IGCPharma

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

Caregiver burden is a critical dimension of Alzheimer’s disease

Recognizing its scope helps inform better clinical priorities, including addressing symptoms like agitation that impact daily life

Learn more about CALMA: https://t.co/BViNki6R50

#AlzheimersCare #AlzheimersDisease

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

As part of caregiver engagement efforts, IGC Pharma joined the caregiver-focused podcast Autumn Is Here to discuss agitation as a clinically significant symptom of Alzheimer’s disease

Read more: https://t.co/q0C0G6bU9l

#AlzheimersDisease #CaregiverSupport

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

Kerwin Medical Center in Dallas has been added as a clinical site in the ongoing Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s disease. Enrollment is now ~80%. 

Read more: https://t.co/XZ1Gv2XZ7n

#AlzheimersResearch

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

IGC Pharma has received authorization in Colombia to synthesize, formulate, and conduct development activities involving psilocybin at its research and development facility in Bogotá.

Read More: https://t.co/ZNcOpRrkZx

#AlzheimersDisease #ClinicalResearch

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

Initiatives like aha™ (Agentic Harmonization Assistant) are designed to help address this integration challenge

Advancing science requires integration at scale

Learn more: https://t.co/NHVOWJ73yv

#AIinHealthcare #DataScience #ResearchInfrastructure

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

#AlzheimersResearch depends on clinical, imaging, and biomarker data collected across institution

But these datasets often use different formats, encodings, and standards

They don’t automatically “speak the same language” ⬇️

[IGC Pharma, Inc. NYSE American: IGC @IGCIR]

Harmonization isn’t just a technical task

It’s research infrastructure

Scalable, interoperable data systems are essential to accelerating Alzheimer’s discovery ⬇️